World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

References

• Abhijnhan A, Adams CE, David A, Ozbilen M. 2007. Depot fluspirilene for schizophrenia. Cochrane Database Syst Rev CD001718.
   Google Scholar
• Adams CE, Fenton MK, Quraishi S, David AS. 2001. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179:290–299.
   PubMed Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, . 2009. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 23:157–162.
   PubMed Web of Science ®Google Scholar
• Alabed S, Latifeh Y, Mohammad HA, Rifai A. 2011. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000203.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, . 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645.
   PubMed Web of Science ®Google Scholar
• Alper K, Schwartz KA, Kolts RL, Khan A. 2007. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62:345–354.
   PubMed Web of Science ®Google Scholar
• Alphs L, Bossie CA, Sliwa JK, Ma YW, Turner N. 2011. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry 10:12.
   PubMed Web of Science ®Google Scholar
• Altamura AC, Glick ID. 2010. Designing outcome studies to determine efficacy and safety of antipsychotics for ‘real world’ treatment of schizophrenia. Int J Neuropsychopharmacol 13:971–973.
   PubMed Web of Science ®Google Scholar
• Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S. 2004. Atypical antipsychotic induced weight gain: pathophysiology and management. Ann Clin Psychiatry 16:75–85.
   PubMedGoogle Scholar
• Anghelescu I, Klawe C, Benkert O. 2000. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 20:716–717.
   Google Scholar
• APA. 1997. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry 154:1–63.
   Web of Science ®Google Scholar
• APA. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65: 267–272.
   PubMed Web of Science ®Google Scholar
• Arman S, Sadramely MR, Nadi M, Koleini N. 2008. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation f risperidone in children and adolescents. Saudi Med J 29: 1130–1134.
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B. 2003. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 18:457–461.
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kologlu M, Tezcan E, Ustundag B, Kilic N. 2004. Nizatidine for the treatment of patients with quetiapine- induced weight gain. Hum Psychopharmacol 19:37–;40.
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. 2004. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18:877–893.
   PubMed Web of Science ®Google Scholar
• Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, . 2010. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 71:103–108.
   PubMed Web of Science ®Google Scholar
• Bai YM, Yu SC, Lin CC. 2003. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo- controlled study. J Clin Psychiatry 64:1342–1348.
   PubMed Web of Science ®Google Scholar
• Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. 2005. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol 20: 79–85.
   Google Scholar
• Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM, . 2006. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 39:135–141.
   PubMed Web of Science ®Google Scholar
• Bai YM, Ting Chen T, Chen JY, Chang WH, Wu B, Hung CH, . 2007. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 68:1218–1225.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, . 2008a. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 9:248–312.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Kasper S, Moller HJ. 2008b. How to grade categories of evidence. World J Biol Psychiatry 9:242–247.
   PubMed Web of Science ®Google Scholar
• Baptista T, Hernandez L, Prieto LA, Boyero EC, de Mendoza S. 2001. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 62:653–655.
   PubMed Web of Science ®Google Scholar
• Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, . 2006. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 51:192–196.
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcategui E, . 2007. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 93:99–108.
   PubMed Web of Science ®Google Scholar
• Baptista T, Uzcategui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, . 2008. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 159:250–253.
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, El Fakih Y, Uzcategui E, Galeazzi T, Beaulieu S, . 2009. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 42:14–19.
   PubMed Web of Science ®Google Scholar
• Barinas-Mitchell E, Kuller LH, Pietropaolo S, Zhang YJ, Henderson T, Pietropaolo M. 2006. The prevalence of the 65-kilodalton isoform of glutamic acid decarboxylase autoantibodies by glucose tolerance status in elderly patients from the cardiovascular health study. J Clin Endocrinol Metab 91:2871–2877.
   Google Scholar
• Bassitt DP, Louza Neto MR. 1998. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 248:209–211.
   Google Scholar
• Bhoopathi PS, Soares-Weiser K. 2006. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 3: CD000205.
   Google Scholar
• Birt J. 2003. Management of weight gain associated with antipsychotics. Ann Clin Psychiatry 15:49–58.
   PubMedGoogle Scholar
• Bliesener N, Yokusoglu H, Quednow BB, Klingmuller D, Kuhn KU. 2004. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report. Pharmacopsychiatry 37:189–191.
   PubMed Web of Science ®Google Scholar
• Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. 1994. Antipsychotic drugs: is more worse?A meta-analysis of the published randomized control trials. Psychol Med 24:307–316.
   Google Scholar
• Borba CP, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC. 2011. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacol 31:653–658.
   PubMed Web of Science ®Google Scholar
• Bradford DW, Perkins DO, Lieberman JA. 2003. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 63:2265–2283.
   PubMed Web of Science ®Google Scholar
• Buchanan RW. 1995. Clozapine: efficacy and safety. Schizophr Bull 21:579–591.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, . 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71–93.
   PubMed Web of Science ®Google Scholar
• Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, . 2003. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 28:527–529.
   PubMed Web of Science ®Google Scholar
• Caroff SN, Mann SC. 1988. Neuroleptic malignant syndrome. Psychopharmacol Bull 24:25–29.
   PubMedGoogle Scholar
• Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, . 2011. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 72:295–303.
   PubMed Web of Science ®Google Scholar
• Carpenter WTJr, Buchanan RW, Kirkpatrick B, Breier AF. 1999. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry 156:299–303.
   PubMed Web of Science ®Google Scholar
• Carriere P, Bonhomme D, Lemperiere T. 2000. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15:321–329.
   PubMed Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, . 2003. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berlin) 166:391–399.
   PubMed Web of Science ®Google Scholar
• Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. 2004. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 65:187–190.
   PubMed Web of Science ®Google Scholar
• Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. 2003. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 13:81–85.
   PubMed Web of Science ®Google Scholar
• Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, . 2006. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes (London) 30:1011–1016.
   PubMed Web of Science ®Google Scholar
• Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML. 2008. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 32:925–931.
   PubMed Web of Science ®Google Scholar
• Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, . 2010. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 341:c4024.
   PubMed Web of Science ®Google Scholar
• Cheung HK. 1981. Schizophrenics fully remitted on neuroleptics for 3–5 years – to stop or continue drugs?Br J Psychiatry 138:490–494.
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, . 2005. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15:111–117.
   PubMed Web of Science ®Google Scholar
• Ciliberto N, Bossie CA, Urioste R, Lasser RA. 2005. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 20:207–212.
   PubMed Web of Science ®Google Scholar
• Citrome L. 2009. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 63: 140–150.
   PubMed Web of Science ®Google Scholar
• Citrome L. 2010. Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 64:216–239.
   PubMed Web of Science ®Google Scholar
• Colonna L, Saleem P, Dondey-Nouvel L, Rein W. 2000. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 15:13–22.
   PubMed Web of Science ®Google Scholar
• Cookson IB. 1987. The effects of a 50% reduction of cis(z)- flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. Int Clin Psychopharmacol 2:141–149.
   Google Scholar
• Correa N, Opler LA, Kay SR, Birmaher B. 1987. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 7:91–95.
   PubMed Web of Science ®Google Scholar
• Correll CU, Schenk EM. 2008. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21:151–156.
   PubMed Web of Science ®Google Scholar
• Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, . 2008. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 28:69–73.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. 1998. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201.
   PubMed Web of Science ®Google Scholar
• Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, . 2010. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol 20:829–838.
   PubMed Web of Science ®Google Scholar
• Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. 1986. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148:120–127.
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. 2002. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 346:16–22.
   PubMed Web of Science ®Google Scholar
• David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. 2005. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev CD000307.
   Google Scholar
• Davis JM. 1975. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 132:1237–1245.
   PubMed Web of Science ®Google Scholar
• Davis JM. 1985. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 46:18–21.
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N. 2003. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 64(Suppl 16):24–33.
   PubMedGoogle Scholar
• Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, . 1993. Dose response of prophylactic antipsychotics. J Clin Psychiatry 54(Suppl):24–30.
   Google Scholar
• Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. 1994. Depot antipsychotic drugs. Place in therapy. Drugs 47:741–773.
   Google Scholar
• Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553–564.
   PubMed Web of Science ®Google Scholar
• De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, . 2006. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2:14.
   PubMedGoogle Scholar
• De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, . 2008. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 101:295–303.
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. 2009. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24:412–424.
   PubMed Web of Science ®Google Scholar
• De Hert M, Hudyana H, Dockx L, Bernagie C, Sweers K, Tack J, . 2010. Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry 26: 34–44.
   Google Scholar
• De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, . 2011a. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10:52–77.
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. 2011b. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114–126.
   PubMed Web of Science ®Google Scholar
• Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, . 2005. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 15:13–21.
   PubMed Web of Science ®Google Scholar
• Desilets AR, Dhakal-Karki S, Dunican KC. 2008. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 42:817–826.
   PubMed Web of Science ®Google Scholar
• Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, . 2010. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 10:43.
   PubMed Web of Science ®Google Scholar
• Detke HC, Zhao F, Garhyan P, Carlson J, McDonnell D. 2011. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol 26:35–42.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Honigfeld G, Patin J. 1991. Clozapine-related seizures. Neurology 41:369–371.
   PubMed Web of Science ®Google Scholar
• DGPPN. 2006. S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 – Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff-Verlag.
   Google Scholar
• Dixon LB, Lehman AF, Levine J. 1995. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 21:567–577.
   PubMed Web of Science ®Google Scholar
• Dixon LB, Perkins B, Calmes C. 2009. Guideline Watch (September 2009): Practice Guideline for the treatment of patients with scizophrenia.
   Google Scholar
• Dupuis B, Catteau J, Dumon JP, Libert C, Petit H. 1987. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 144:802–805.
   Google Scholar
• Dursun SM, Devarajan S. 2000. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 45:198.
   PubMed Web of Science ®Google Scholar
• El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. 2006. Non-neuroleptic catecholaminergic drugs for neuroleptic- induced tardive dyskinesia. Cochrane Database Syst Rev CD000458.
   Google Scholar
• Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. 2004. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65:696–701.
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. 2008. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 23:325–331.
   PubMed Web of Science ®Google Scholar
• Essock SM, Hargreaves WA, Covell NH, Goethe J. 1996. Clozapine’s effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 32:683–697.
   PubMedGoogle Scholar
• Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. 2006. Effectiveness of switching antipsychotic medications. Am J Psychiatry 163:2090–2095.
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. 2005. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6:132–191.
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. 2006. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7:5–40.
   PubMed Web of Science ®Google Scholar
• Farinde A. 2011. The impact of topiramate (Topamax(R)) therapy on the development of aggressive and/or agitated behavior. J Pharm Pract 24:568–570.
   Google Scholar
• Faulkner G, Cohn T, Remington G. 2007a. Interventions to reduce weight gain in schizophrenia. Schizophr Bull 33:654–656.
   PubMed Web of Science ®Google Scholar
• Faulkner G, Cohn T, Remington G. 2007b. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev CD005148.
   Google Scholar
• Fleischhacker WW, Roth SD, Kane JM. 1990. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 10:12–21.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Hummer M. 1997. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 53:915–929.
   Google Scholar
• Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, . 2011. A randomized trial of palipe ridone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol Jul 22:1–12. Epub ahead of print].
   Google Scholar
• Floris M, Lejeune J, Deberdt W. 2001. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 11:181–182.
   PubMed Web of Science ®Google Scholar
• Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M, . 2002. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 53:145–159.
   PubMed Web of Science ®Google Scholar
• Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, . 2007. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 68:1763–1774.
   PubMedGoogle Scholar
• Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, . 2010. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 35:2367–2377.
   PubMed Web of Science ®Google Scholar
• Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, . 2011. Relapse prevention in first-episode schizophrenia – maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 72:205–218.
   PubMed Web of Science ®Google Scholar
• Ganguli R. 2007. Behavioral therapy for weight loss in patients with schizophrenia. J Clin Psychiatry 68 (Suppl 4):19–25.
   PubMedGoogle Scholar
• Ganguli R, Brar JS, Garbut R, Chang CC, Basu R. 2011. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses 5:75–79.
   PubMedGoogle Scholar
• Gilbert PL, Harris MJ, McAdams LA, Jeste DV. 1995. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52:173–188.
   PubMed Web of Science ®Google Scholar
• Glassman AH, Bigger JT Jr. 2001. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158:1774–1782.
   PubMed Web of Science ®Google Scholar
• Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, . 2011. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry 72:1616–1627.
   PubMed Web of Science ®Google Scholar
• Goff DC, Hill M, Freudenreich O. 2010. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 71 (Suppl 2):20–26.
   Google Scholar
• Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. 2010a. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 26:377–387.
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, . 2010b. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 25:247–256.
   PubMed Web of Science ®Google Scholar
• Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. 2011. A 52–week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 25:685–697.
   PubMed Web of Science ®Google Scholar
• Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. 2005. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162:1744–1746.
   PubMed Web of Science ®Google Scholar
• Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, . 2006. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 86:234–243.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, . 2011. Does long-acting injectable risperidone make a difference to the real–life treatment of schizophrenia?Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 134:187–194.
   Google Scholar
• Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, . 2009. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10:85–116.
   PubMed Web of Science ®Google Scholar
• Gupta S, Masand PS, Virk S, Schwartz T, Hameed A, Frank BL, . 2004. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 70:57–62.
   PubMed Web of Science ®Google Scholar
• Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, . 2011. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72:1222–1228.
   PubMed Web of Science ®Google Scholar
• Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. 1998. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18:41–49.
   PubMed Web of Science ®Google Scholar
• Hamilton SH, Edgell ET, Revicki DA, Breier A. 2000. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 15:245–255.
   PubMed Web of Science ®Google Scholar
• Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D. 2007. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17:235–244.
   PubMed Web of Science ®Google Scholar
• Harrison TS, Goa KL. 2004. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 18:113–132.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, . 2012. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318–378.
   PubMed Web of Science ®Google Scholar
• Hay DP, Hay L, Blackwell B, Spiro HR. 1990. ECT and tardive dyskinesia. J Geriatr Psychiatry Neurol 3:106–109.
   Google Scholar
• Heimberg C, Gallacher F, Gurc FC, Gur RE. 1995. Diet and gender moderate clozapine-related weight gain. Hum Psychopharmacol 10:376–371.
   Google Scholar
• Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, . 2005a. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 162:954–962.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Louie PM, Koul P, Namey L, Daley TB, Nguyen DD. 2005b. Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Ann Clin Psychiatry 17:95–97.
   PubMedGoogle Scholar
• Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, . 2007. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 115:101–105.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, . 2009. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand 119:457–465.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Freudenreich O, Borba CP, Wang X, Copeland PM, Macklin E, . 2011. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res 130:53–56.
   Google Scholar
• Hill AL, Sun B, Karagianis JL, Watson SB, McDonnell DP. 2011. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry 11:28.
   PubMed Web of Science ®Google Scholar
• Hoffmann VP, Case M, Jacobson JG. 2012. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. J Clin Psychiatry 73:216 23.
   Google Scholar
• Hogarty GE, Ulrich RF. 1998. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 32:243–250.
   PubMed Web of Science ®Google Scholar
• Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, . 1988. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Arch Gen Psychiatry 45:797–805.
   PubMed Web of Science ®Google Scholar
• Holt RI, Peveler RC. 2011. Antipsychotics and hyperprolac tinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxford) 74:141–147.
   PubMedGoogle Scholar
• Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, . 2009. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33:1022–1031.
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. 2010. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 116:107–117.
   PubMed Web of Science ®Google Scholar
• Jean-Baptiste M, Tek C, Liskov E, Chakunta UR, Nicholls S, Hassan AQ, . 2007. A pilot study of a weight management program with food provision in schizophrenia. Schizophr Res 96:198–205.
   PubMed Web of Science ®Google Scholar
• Jeste DV, Lacro JP, Gilbert PL, Kline J, Kline N. 1993. Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 19:817–830.
   PubMed Web of Science ®Google Scholar
• Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, . 2008. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69:706–711.
   PubMed Web of Science ®Google Scholar
• Johnson DA. 1976. The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand 53:298–301.
   PubMedGoogle Scholar
• Johnson DA, Ludlow JM, Street K, Taylor RD. 1987. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br J Psychiatry 151:634–638.
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, . 2006. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, . 2008. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097.
   PubMed Web of Science ®Google Scholar
• Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. 1982. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 39:70–73.
   PubMed Web of Science ®Google Scholar
• Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, . 1983. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 40:893–896.
   Google Scholar
• Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, . 2002. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 159:554–560.
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. 2003. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125–1132.
   PubMed Web of Science ®Google Scholar
• Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, . 2010. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 167:181–189.
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Kawamura I, Fujii A, Ohmori T. 2004. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia. Neuro Endocrinol Lett 25:135–140.
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, . 2003. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325–337.
   PubMed Web of Science ®Google Scholar
• Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M. 2006. Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res 81:139–143.
   PubMed Web of Science ®Google Scholar
• Keks NA, Ingham M, Khan A, Karcher K. 2007. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 191:131–139.
   PubMed Web of Science ®Google Scholar
• Kilian R, Steinert T, Schepp W, Weiser P, Jaeger S, Pfiffner C, . 2012. Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. Eur Arch Psychiatry Clin Neurosci 262:589 598.
   PubMed Web of Science ®Google Scholar
• Kim JH, Yim SJ, Nam JH. 2006. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 82:115–117.
   PubMed Web of Science ®Google Scholar
• Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, . 2002. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 63:408–413.
   PubMed Web of Science ®Google Scholar
• Kimiagar I, Dobronevsky E, Prokhorov T, Miniovitz A, Rabey JM. 2011. Rapid improvement of tardive dyskinesia with tetra benazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study. J Neurol 259:660 664.
   Google Scholar
• Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. 2004. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 28:985–996.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. 2006. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31:577–588.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. 2011. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry, Nov 29. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Kissling W. 1991. Guidelines for neuroleptic relapse prevention in schizophrenia. Kissling W, ed. Berlin: Springer.
   Google Scholar
• Kissling W, Glue P, Medori R, Simpson S. 2007. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol 22:505–513.
   PubMed Web of Science ®Google Scholar
• Ko YH, Joe SH, Jung IK, Kim SH. 2005. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28:169–175.
   PubMed Web of Science ®Google Scholar
• Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, . 2010. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 13:635–647.
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. 2010. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 36:94–103.
   PubMed Web of Science ®Google Scholar
• Kumar R, Sachdev PS. 2009. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 22:293–299.
   PubMed Web of Science ®Google Scholar
• Kutcher S, Williamson P, MacKenzie S, Marton P, Ehrlich M. 1989. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double- blind, placebo-controlled study. J Clin Psychopharmacol 9:403–406.
   PubMed Web of Science ®Google Scholar
• Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, . 2006. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 67:1690–1697.
   PubMed Web of Science ®Google Scholar
• Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. 2005. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 72:249–258.
   PubMed Web of Science ®Google Scholar
• Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. 2008. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 69:790–799.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. 2009. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 66:713–720.
   PubMed Web of Science ®Google Scholar
• Lee BH, Kim YK, Park SH. 2006. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 30:714–717.
   PubMed Web of Science ®Google Scholar
• Lee MS, Song HC, An H, Yang J, Ko YH, Jung IK, . 2010. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci 64:19–27.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, . 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161:1–56.
   PubMed Web of Science ®Google Scholar
• Lerner V, Bergman J, Statsenko N, Miodownik C. 2004. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 65:1550–1554.
   Google Scholar
• Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. 2003. Relapse prevention in schizophrenia with new- generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209–1222.
   PubMed Web of Science ®Google Scholar
• Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. 2009a. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429–447.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. 2009b. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41.
   PubMed Web of Science ®Google Scholar
• Leucht S, Kissling W, Davis JM. 2009c. How to read and understand and use systematic reviews and meta-analyses. Acta Psychiatr Scand 119:443–450.
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. 2011a. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127:83–92.
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S, Kissling W, Davis JM. 2011b. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 14:269–284.
   Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. 2012a. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 5:CD008016.
   Google Scholar
• Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, . 2012b. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071.
   PubMed Web of Science ®Google Scholar
• Leung JG, Breden EL. 2011. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 45:525–531.
   PubMed Web of Science ®Google Scholar
• Li H, Rui Q, Ning X, Xu H, Gu N. 2011. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35:1002–1008.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. 1991. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503–510.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, . 2003. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28:995–1003.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, . 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. 2002. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev CD001950.
   Google Scholar
• Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K. 2004a. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev CD001946.
   Google Scholar
• Lima AR, Weiser KV, Bacaltchuk J, Barnes TR. 2004b. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev CD003727.
   Google Scholar
• Lindenmayer JP, Khan A. 2011. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res 125:267–277.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S. 2007. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 17:138–144.
   PubMed Web of Science ®Google Scholar
• Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. 2003. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 35:237–241.
   PubMed Web of Science ®Google Scholar
• Lopez-Mato A, Rovner J, Illa G, Vieitez A, Boullosa O. 2003. [Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration]. Vertex 14:85–96.
   PubMedGoogle Scholar
• Louza MR, Bassitt DP. 2005. Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years’ follow-up. J Clin Psychopharmacol 25:180–182.
   PubMed Web of Science ®Google Scholar
• Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. 2004. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65:766–771.
   PubMed Web of Science ®Google Scholar
• Lu ML, Shen WW, Chen CH. 2008. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 32:1978–1981.
   PubMed Web of Science ®Google Scholar
• Lyons MK. 2011. Deep brain stimulation: current and future clinical applications. Mayo Clin Proc 86:662–72.
   PubMed Web of Science ®Google Scholar
• Mahmoud R, Engelhart L, Ollendorf D, Oster G. 1999. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry 60 (Suppl 3):42–47; discussion 48.
   Google Scholar
• Manu P, Sarpal D, Muir O, Kane JM, Correll CU. 2011. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 134:180–186.
   Google Scholar
• Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, . 1984. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41:1025–1029.
   PubMed Web of Science ®Google Scholar
• Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, . 2003. Maintenance treatment of schizo phrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 160:1405–1412.
   PubMed Web of Science ®Google Scholar
• Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, . 2004. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334–1349.
   PubMed Web of Science ®Google Scholar
• Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G. 1986. Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Jpn J Psychiatry Neurol 40:639–646.
   Google Scholar
• Mauri M, Castrogiovanni S, Simoncini M, Iovieno N, Miniati M, Rossi A, . 2006. Effects of an educational intervention on weight gain in patients treated with antipsychotics. J Clin Psychopharmacol 26:462–466.
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, . 2010. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 10:45.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, . 2007. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1050–1060.
   PubMed Web of Science ®Google Scholar
• Melamed E, Achiron A, Shapira A, Davidovicz S. 1991. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome?Clin Neuropharmacol 14:273–278.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, . 2003. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82–91.
   PubMed Web of Science ®Google Scholar
• Mendhekar DN, Jiloha RC, Mehndiratta MM, War L. 2002. Challenge with atypical antipsychotic drugs in risperidone induced neuroleptic malignant syndrome: a case report. Indian J Psychiatry 44:387–390.
   PubMedGoogle Scholar
• Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. 2004. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 65:471–477.
   PubMed Web of Science ®Google Scholar
• Miller DD. 2000. Review and management of clozapine side effects. J Clin Psychiatry 61 (Suppl 8):14–17; discussion 18–19.
   Google Scholar
• Miller DE, Sebastian CS. 2005. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. J Clin Psychiatry 66:269–270.
   PubMed Web of Science ®Google Scholar
• Miodownik C, Lerner V, Statsenko N, Dwolatzky T, Nemets B, Berzak E, . 2006. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin Neuropharmacol 29:68–72.
   Google Scholar
• Moller HJ. 2004. Novel antipsychotics in the long-term treatment of schizophrenia. World J Biol Psychiatry 5:9–19.
   PubMed Web of Science ®Google Scholar
• Moller HJ. 2008. Do effectiveness (“real world”) studies on antipsychotics tell us the real truth?Eur Arch Psychiatry Clin Neurosci 258:257–270.
   PubMed Web of Science ®Google Scholar
• Möller HJ, van Zerssen D. 1995. Course and outcome of schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford:Blackwell.
   Google Scholar
• Montgomery SA, van Zwieten-Boot B. 2007. ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March2004. Eur Neuropsychopharmacol 17:70–77.
   Google Scholar
• Mukundan A, Faulkner G, Cohn T, Remington G. 2010. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev CD006629.
   Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, Mico U, Bellinghieri PM, Scimeca G, . 2011. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol 25:667–674.
   PubMed Web of Science ®Google Scholar
• Naber D, Lambert M. 2009. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 23:649–659.
   PubMed Web of Science ®Google Scholar
• Narula PK, Rehan HS, Unni KE, Gupta N. 2010. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 118:218–223.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. 2007. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115:260–267.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, . 2010. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 35:2072–2082.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. 2007. Metabolic syndrome and mental illness. Am J Manag Care 13:S170–177.
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, . 2008. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 69:1046–1056.
   PubMed Web of Science ®Google Scholar
• NICE. 2002. National Institute of Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guideance No. 54. www.nice.org.ik.
   Google Scholar
• NICE. 2010. The NICE Guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). London: The British Psychological Society.
   Google Scholar
• Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. 2011. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 25:473–490.
   PubMed Web of Science ®Google Scholar
• Norgard NB, Stark JE. 2006. Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 26:1180–1182.
   PubMed Web of Science ®Google Scholar
• Odejide OA, Aderounmu AF. 1982. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J Clin Psychiatry 43:195–196.
   Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, . 2009. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24:287–296.
   PubMed Web of Science ®Google Scholar
• Pacia SV, Devinsky O. 1994. Clozapine-related seizures: experience with 5,629 patients. Neurology 44:2247–2249.
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, . 2010. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 30:235–244.
   PubMed Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, . 2011. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35:218–226.
   PubMed Web of Science ®Google Scholar
• Patel MX, Taylor M, David AS. 2009. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl 52:S1–4.
   PubMedGoogle Scholar
• Pope HGJr, Aizley HG, Keck PEJr, McElroy SL. 1991. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry 52:208–212.
   Google Scholar
• Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, . 2006. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 85:254–265.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, . 2002. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 159:1058–1060.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. 2004. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 14:332–336.
   PubMed Web of Science ®Google Scholar
• Praharaj SK, Jana AK, Goyal N, Sinha VK. 2011. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol 71:377–382.
   PubMed Web of Science ®Google Scholar
• Pujalte D, Bottai T, Hue B, Alric R, Pouget R, Blayac JP, . 1994. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol 17:236–242.
   PubMed Web of Science ®Google Scholar
• Purgato M, Adams CE. 2011. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev 9:CD001719.
   Google Scholar
• Quaraishi SN, David A, Brasil MA, Alheriar FV. 1999Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev2004;(3):CD001719.
   Google Scholar
• Rabinowitz J, Hornik T, Davidson M. 2001. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry 62: 343–346.
   PubMedGoogle Scholar
• RANZCP. 2005. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry 39:1–30.
   PubMed Web of Science ®Google Scholar
• Rathbone J, Soares-Weiser K. 2011. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev CD003727.
   Google Scholar
• Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, . 2008. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res 35:215–225.
   PubMed Web of Science ®Google Scholar
• Reulbach U, Dutsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J, . 2007. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 11:R4.
   Web of Science ®Google Scholar
• Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. 1999. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 8:417–426.
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, . 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241–247.
   PubMed Web of Science ®Google Scholar
• Roden DM. 2004. Drug-induced prolongation of the QT interval. New Engl J Med 350:1013–1022.
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, . 1997. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New Engl J Med 337:809–815.
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, . 1998. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health Serv Res 33:1237–1261.
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, . 1999. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Am J Psychiatry 156:88–93.
   Google Scholar
• Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, . 2003. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. J Am Med Assoc 290:2693–2702.
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, . 2006. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 163: 2080–2089.
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, . 2009. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 107:22–29.
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, . 2011. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New Engl J Med 364:842–851.
   PubMed Web of Science ®Google Scholar
• Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. 2006. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51:531–539.
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Guarneri L, Bravi D. 2000. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 48:167–168.
   PubMed Web of Science ®Google Scholar
• Sakkas P, Davis JM, Janicak PG, Wang ZY. 1991. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 27:381–384.
   PubMedGoogle Scholar
• Sako W, Goto S, Shimazu H, Murase N, Matsuzaki K, Tamura T, . 2008. Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia. Mov Disord 23: 1929–1931.
   PubMed Web of Science ®Google Scholar
• Saleem P, Olie JP, Loo H. 2002. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. Int Clin Psychopharmacol 17:1–8.
   PubMed Web of Science ®Google Scholar
• Sampath G, Sha A, Krska J, Soni S. 1992. Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neurolepti levels. Human Psychopharmacol Clin Exp 7:255–264.
   Google Scholar
• Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, . 2005. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 162:947–953.
   PubMed Web of Science ®Google Scholar
• Schooler NR. 1993. Reducing dosage in maintenance treatment of schizophrenia. Review and prognosis. Br J Psychiatry Suppl 22:58–65.
   Google Scholar
• Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, . 1997. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 54:453–463.
   PubMed Web of Science ®Google Scholar
• Semple D, Smyth R. 2009. Oxford Handbook of Psychiatry. Oxford: Oxford University Press.
   Google Scholar
• Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, . 2007. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 164:1404–1410.
   PubMed Web of Science ®Google Scholar
• Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, . 2006. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 67:1194–1203.
   PubMed Web of Science ®Google Scholar
• Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E. 1990. Acute dystonia during fixed-dose neuroleptic treatment. J Clin Psychopharmacol 10:389–396.
   Google Scholar
• Sliwa JK, Bossie CA, Ma YW, Alphs L. 2011. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res 132:28–34.
   PubMed Web of Science ®Google Scholar
• Soares-Weiser KV, Joy C. 2003. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000208.
   Google Scholar
• Soares KV, McGrath JJ. 2000. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000204.
   Google Scholar
• Soares-Weiser K, Rathbone J. 2004. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000206.
   Google Scholar
• Soares-Weiser K, Rathbone J. 2006. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev CD000459.
   Google Scholar
• Soares-Weiser K, Maayan N, McGrath J. 2011. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000209.
   Google Scholar
• Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, . 1997. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 58:318–322.
   PubMedGoogle Scholar
• Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, . 2005. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res 78:161–169.
   Google Scholar
• Strawn JR, Keck PEJr, Caroff SN. 2007. Neuroleptic malignant syndrome. Am J Psychiatry 164:870–876.
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, . 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611–622.
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, . 2007. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164:415–427.
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, . 2009. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107:1–12.
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, . 2011. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168:947–956.
   PubMed Web of Science ®Google Scholar
• Stryjer R, Rosenzcwaig S, Bar F, Ulman AM, Weizman A, Spivak B. 2010. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol 33:219–222.
   PubMedGoogle Scholar
• Sumic JC, Baric V, Bilic P, Herceg M, Sisek-Sprem M, Jukic V. 2007. QTc and psychopharmacs: are there any differences between monotherapy and polytherapy. Ann Gen Psychiatry 6:13.
   Google Scholar
• Supprian T. 2004. Therapie. In: Assion HJ, Volz HP, eds. Malgnes neuroleptisches Syndrom. Stuttgart, New York: Thieme. p. 28–34.
   Google Scholar
• Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, . 2007. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 164:428–436.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. 2012. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 134:219–225.
   PubMed Web of Science ®Google Scholar
• Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. 2002. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000207.
   Google Scholar
• Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. 1994. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 55 (Suppl B): 102–106.
   Google Scholar
• Tchoukhine E, Takala P, Hakko H, Raidma M, Putkonen H, Rasanen P, . 2011. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 72:326–330.
   PubMed Web of Science ®Google Scholar
• Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J. 2005. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 66:1130–1133.
   PubMed Web of Science ®Google Scholar
• Tenback DE, van Harten PN, Slooff CJ, van Os J. 2010. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol 24:1031–1035.
   PubMed Web of Science ®Google Scholar
• Thobois S, Poisson A, Damier P. 2011. Surgery for tardive dyskinesia. Int Rev Neurobiol 98:289–296.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvarinen S, Eronen M, . 2005. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 66:1012–1015.
   PubMed Web of Science ®Google Scholar
• Trollor JN, Sachdev PS. 1999. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust NZ J Psychiatry 33:650–659.
   PubMed Web of Science ®Google Scholar
• Trottenberg T, Volkmann J, Deuschl G, Kuhn AA, Schneider GH, Muller J, . 2005. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 64:344–346.
   PubMed Web of Science ®Google Scholar
• Ucok A, Ucok G. 1996. Maintenance ECT in a patient with catatonic schizophrenia and tardive dyskinesia. Convuls Ther 12:108–112.
   Google Scholar
• Umbricht D, Flury H, Bridler R. 2001. Cognitive behavior therapy for weight gain. Am J Psychiatry 158:971.
   PubMed Web of Science ®Google Scholar
• Venkatasubramanian G, Arasappa R, Rao NP, Behere RV, Gangadhar BN. 2010. Adjuvant metformin worsens psychosis in schizophrenia: a case report. Prim Care Companion J Clin Psychiatry. 12(2). pii: PCC.09l00801.
   Google Scholar
• Vinson DR, Drotts DL. 2001. Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. Ann Emerg Med 37:125–131.
   PubMed Web of Science ®Google Scholar
• Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. 2000. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 43:135–145.
   PubMed Web of Science ®Google Scholar
• Walburn J, Gray R, Gournay K, Quraishi S, David AS. 2001. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179:300–307.
   PubMed Web of Science ®Google Scholar
• Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, . 2010. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry 167:676–685.
   PubMed Web of Science ®Google Scholar
• Wang Y, Turnbull I, Calne S, Stoessl AJ, Calne DB. 1997. Pallidotomy for tardive dyskinesia. Lancet 349:777–778.
   PubMed Web of Science ®Google Scholar
• Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W, Schimmelmann BG, . 2008. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. J Psychiatr Res 42:676–683.
   Google Scholar
• Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. 1987. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 144:1148–1153.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Daniel DG, Simpson G, Romano SJ. 2003a. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23:595–600.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Simpson GM, Potkin SG, O’Sullivan RL. 2003b. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 64:580–588.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, Locklear J. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55:886–891.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. 2008. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33:985–994.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. 2009. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 70:1397–1406.
   PubMed Web of Science ®Google Scholar
• Wells AJ, Sommi RW, Crismon ML. 1988. Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm 22:475–480.
   PubMedGoogle Scholar
• Werneke U, Taylor D, Sanders TA, Wessely S. 2003. Behavioural management of antipsychotic-induced weight gain: a review. Acta Psychiatr Scand 108:252–259.
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. 2002. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856–865.
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, . 2008. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 165:352–358.
   PubMed Web of Science ®Google Scholar
• Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. 2007. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 68:654–661.
   PubMed Web of Science ®Google Scholar
• Yuan HN, Wang CY, Sze CW, Tong Y, Tan QR, Feng XJ, . 2008. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol 28:264–370.
   PubMed Web of Science ®Google Scholar